Evidence map›Paper›PMID 31285810›Full record

ArticleHematology reports2019

B-cell acute lymphoblastic leukemia as a secondary malignancy following diffuse large B-cell lymphoma.

Daria Gaut, Anthony Bejjani, Joshua Sasine, Gary Schiller

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Daria GautDepartment of Medicine.
Anthony BejjaniDivision of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, CA, USA.
Joshua SasineDivision of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, CA, USA.
Gary SchillerDivision of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, CA, USA.
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secondary acute lymphoblastic leukemia (ALL) is a rare disease that has not been well characterized compared with secondary myelodysplastic syndrome or secondary acute myeloid leukemia. We present a report of two patients who developed ALL following complete remission of diffuse large B-cell lymphoma (DLBCL). The first case is more consistent with a therapy- related ALL as a PCR analysis of bone marrow aspirate revealed a distinct clone and the mixed-lineage leukemia gene rearrangement, commonly associated with exposure to topoisomerase II inhibitors. The second case is more consistent with clonal evolution given positive MYC and BCL2 fusion signals in the original diagnosis of DLBCL and the secondary ALL.

Indexed as

acute lymphoblastic leukemiadiffuse large B-cell lymphomasecondary acute lymphoblastic leukemiasecondary malignancytherapy-related acute lymphoblastic leukemia

Identifiers

PMID31285810
PMCPMC6589539
OpenAlexW2950719734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.